[1] 国家食品药品监督管理总局.药品不良反应信息通报(第64期)警惕阿德福韦酯的低磷血症及骨软化风险[EB/OL].(2014-12-08)[2015-05-27].http://www.sfda.gov.cn/WS01/CL0078/110541.html. [2] Hadziyannis S J,Tassopoulos N C,Heathcote E J,et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751. [3] IzzedineH,Hulot J S,Launay-Vacher V,et al.Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind Randomized placebo-controled studies[J].Kidney Int,2004,66(3):1153-1158. [4] Cihlar T,Lin D C,Pritchard J B,et al.The antiviral nucleotide analogs eidofovir and adefovir are novel substrates for human and rat renal organic anion transporter[J].Mol Pharmacol,1999,56(3):570-580. [5] Ho E S,Lin D C,Mendel D B,et al.Cytotoxicity of antiviral nucleotides adefovir and eidofovir is induced by the expression of human renal organic anion transporter[J].J Am Soc Nephrol,2000,11(3):383-393. [6] Mocanu B,Holt B.Renal tubular acidosis with Fanconi syndrome associated with enofovir [J].Ame J Kidney Dis,2008,51(4) :70. [7] Lee J C,Marosok R D.Acute tubular necrosis in a patient receiving tenofovir[J].AIDS,2003,17(17):2543-2544. [8] Izzedine H,Kheder Elfekih R,Housset P,et al.Adefovir dipivoxil-induced acute tubular necr osis and Fanconi syndrome in a renal transplant patient[J] .AIDS,2009,23 (4):544-545. [9] 孙晓方,张化冰,李新萍,等.阿德福韦酯导致低血磷性骨软化症一例并文献复习[J].中华内科杂志,2011,50(9) :754-757. [10] 田月洁,王金英,谢彦军,等.阿德福韦酯治疗乙肝致低血磷性骨软化症的现状分析[J].中国药物警戒,2013,10(5) :294-298. [11] 王晓今,傅青春,臧祖胜,等.表现为范可尼综合征的阿德福韦酯相关慢性肾病15例分析[J].肝脏,2014,19(7):475-478. |